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The regulation of male reproductive function today is not limited to surgical castration; there are many other 
methods of controlling reproductive function. Non-surgical methods of controlling male reproductive function 
can be reversible and not reversible, i.e., reproductive function is preserved or completely suppressed. Castra-
tion of males or orchiectomy leads to irreversible sterility of the male, when the male completely loses the 
ability to reproduce. This operation can also entail some side effects: obesity, underdevelopment of the external 
genital organs, an increased risk of diabetes or hypothyroidism, problems with frequent urination and behavior-
al problems. Therefore, methods of non-surgical management of reproductive function and contraception in 
males are being actively developed. The article presents the latest methods of contraception and the manage-
ment of the reproductive function of male domestic animals (cats, dogs): clinical application GnRH and ago-
nists GnRH, Non-Peptide GnRH Antagonists, GnRH-Toxin Conjugate, GnRH Vaccines and other immune 
contraceptive vaccines, chemical sterilants for intratesticular injections, calcium chloride, zinc gluconate, 
chlorhexidine digluconate, hypertonic saline, sex steroids (progestines), gene silencing, kisspeptin and GnIH, 
targeting delivery of cytotoxins, single-dose hormonal male and female sterilianr, FSH – receptor ligand cyto-
toxin conjugates, Sperm Protein Reactive with Antisperm Antibodies (SPRASA) Reversible Inhibition of 
Sperm under Guidance(RISUG). 
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Male dogs and cats are castrated under general anesthe-
sia. Incisions or an incision is made in the scrotum (pre-
scrotal incisions are most common in the US in dogs) and 
each testicle is exteriorized, the blood supply and spermatic 
cord are ligated, and the incision is closed in dogs or (com-
monly) left open in cats. Typically, the procedure is com-
pleted quickly and risk of infection is low. Some veterinari-
ans recommend this surgery for dogs that have not yet 
reached sexual maturity to prevent them from developing 
aggressive behavior, in the belief that castration eliminates 
testosterone, and reduction in testosterone will result in a 
reduction in aggression, but there is controversy on the rela-
tionship of aggressive behavior to sex steroids. Castration 
may not result in decreased aggression. Although there has 
been concern that the urethral diameter is decreased in male 
cats following prepubertal castration, numerous studies have 
found no correlation between castration and urethral diame-
ter or lower urinary tract disease (Kustritz, 2010).  
One alternative to surgical castration in males is a vasec-
tomy; however, this procedure is not widely performed in 
part because it does not affect undesirable aggressive behav-
ior (Cathey & Memon, 2010).  
However, there are other non-surgical methods of regu-
lating sexual function and contraception in male domestic 
animals that can be completely reversible or irreversible. 
These methods can eliminate the aggressive behavior of 
males, as well as prevent the development of prostate dis-
eases. 
 
2. Results and discussion 
 
Gonadotropin-Releasing Hormone (GnRH) 
There are three major considerations governing interven-
tions to create fertility suppression at the level of GnRH: 
1. Potentially effective in males and females. 
2. Potentially effective in canine and feline species, be-
cause GnRH is highly conserved (i.e., the gene coding for 
GnRH results in the translation of the same decapeptide with 
the ame sequence of amino-acids among mammals). 
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3. Suppression  of  GnRH  will  result  in  suppression  of
the  secretion  of  the  reproductive  steroid  hormones and 
therefore  suppress  sexual  behavior  and  hormonemediated 
diseases as well as fertility. 
Concern  has  been  expressed  that  since  GnRH receptors 
exist  outside  the  pituitary  gland  and  reproductive  tract, ap-
proaches  targeting  GnRH  may  have  effects  on  non-target 
tissues.  However,  no  such  effects  have  been  identified de-
spite more than a decade of treatment with these approaches 
(Rhodes, 2017). 
GnRH Agonists 
Effective GnRH agonists, which mimic the effect of na-
tive GnRH but have a longer half-life in the blood, work by 
binding to and causing down-regulation of the GnRH recep-
tors in the pituitary gland. The continuous administration of 
agonists  (as  opposed  to  the  normal pulsatile  release  of  en-
dogenous  GnRH)  results  in  a  complete  suppression  of
GnRH  effect,  since  to  be  effective, GnRH  must  be  “seen”  
through the receptors in the pituitary cells (Gobello, 2007).  
GnRH  agonists  have  been  developed  for  use  in  human 
medicine and are available as generic peptide drugs such as 
leuprolide,  nafarelin,  triptorelin,  and  histerelin.  These pep-
tides have to be given by injection or subcutaneous implan-
tation,  because  if  given  orally,  they  are  digested  and not 
biologically  active.  Effective  slow-release  implants  have 
been developed for humans that are used for 3–12 months to 
suppress testosterone in the treatment of prostate cancer and 
to  suppress  estrogen  in  the  treatment  of  endometriosis
(Gobello, 2007). 
Another  GnRH agonist  – deslorelin – was developed in 
an implant formulation for use in dogs and has been used in 
both  domestic  animals  and  wildlife.  A  disadvantage  of  the  
GnRH agonist approach to suppress reproductive activity is 
that  initial  administration  in  males  typically  causes  the  in-
crease in LH causes an increase in testosterone that does not 
express  itself  clinically.  This  initial  stimulation  is  called  a  
“flare.” It is important to understand that  the mechanism of 
action of GnRH agonists is  characterized by flares of vary-
ing duration and that GnRH agonists are therefore not effec-
tive  in  situations  in  which  an  immediate  suppression  of
fertility is  desired.  Once  the  agonist  is  discontinued,  either 
byremoving  an  implant,  or  depletion  of  the  active  drug  or  
stopping  daily  administration  of  the  injectable  form  of  the  
drug,  the  return-to-fertility  timeframe  is  unpredictable
(Goericke-Pesch et al., 2013). 
One product, Suprelorin® (deslorelin implant), is availa-
ble as a 6-month (4.7 mg) or 12-month (9.4 mg) implant for 
use  in  male  dogs.  Suprelorin  was  developed,  approved  by  
regulatory  bodies  and  launched  in  Australia  and  New Zea-
land  by  Peptech  Animal  Health.  Research  has  shown  that  
Suprelorin is also effective in fertility suppression in bitches 
and in male and female cats (Goericke-Pesch et al., 2011).  
Note  that  in  addition  to  contraception,  GnRH  agonists  
also cause significant shrinkage of the prostate gland, which 
is a clinical advantage for dogs with benign prostatic hyper-
plasia, a common condition of older intact male dogs. Dogs 
with clinical signs of prostate disease are typically castrated 
to  shrink  the  prostate,  so  treatment  with  a  GnRH  agonist
could  be  of  benefit  for  dogs  suffering  from  this  condition 
(Limmanont et al., 2011). 
Deslorelin 
Deslorelin  in  Dogs  – Males.  Researchers  reported  a
mean duration of efficacy of 89 weeks, with a range of 56–
132 weeks (Trigg & Yeates, 2008). 
Suprelorin is used more often to pharmacologically cas-
trate  males.  The  implant  can  be  given  routinely  every  six  
months or when the increase in testicular size indicates that 
it has stopped working (Goericke-Pesch et al., 2011). 
Suprelorin  on  male  cats.  Duration  of  efficacy  – as  ob-
served  from  clinical  experiences  – varied  between  six  and  
24  months.  Return  of  spermatogenesis  to  pre-treatment 
semen quality may take up to five – six months; initial return 
can  be  expected  in  five  to  nine  weeks”  (Novotny  et  al.,
2012). 
Other GnRH Agonists 
The GnRH agonist leuprolide acetate, given to dogs as a 
single injected dose at 1 mg/kg, causes spermatozoa abnor-
malities  and  significantly  decreases  ejaculate  volume  and
testosterone  and  LH  concentrations  for  6  weeks.  In  one
study,  normal  spermatogenesis  resumed  20  weeks  after
treatment (Lacoste et al., 1989). Buserelin implants (6.6 mg) 
decreased  testosterone  concentrations  in  male  dogs  and
produced infertility within 3  weeks;  the effect  persisted for  
an average of 233 days (Kutzler & Wood, 2006).  
But a significant drawback of these drugs is that they are 
not  registered  for  animals  and  the  dosage  forms  that  are
described are used only in humane medicine. 
Non-Peptide GnRH Antagonists 
Non-peptide  (small  molecule)  GnRH  antagonists have 
the potential to be developed as oral, mucosal, and/or dermal 
formulations  delivered  via  drug-release technologies  that
differ  from  typical  peptide-release implants.  These  small
molecule GnRH antagonists show species differences: They 
were designed to bind the human GnRH receptor and block 
activity.  They  are  significantly  smaller  than  the  peptide 
antagonists;  the  larger  GnRH  peptide  antagonists  will  bind 
the  GnRH  receptors  in  rats,  humans,  dogs  and  likely  most 
all  mammalian  species,  showing  cross-species  activity
(Concannon, 2006). 
However,  it  has been demonstrated that the small mole-
cule drugs  do  not  work  in  all  species.  Although  they  bind  
and antagonize  the  GnRH  receptor  in  some  species,  minor 
differences  in  the  receptor  structure  between  species  can 
result  in  a  particular  compound  being  effective  in  rats and 
humans, for example, but not in dogs. Therefore it cannot be 
assumed  that  small  molecule  GnRH  compounds developed 
for  use  in  human  health  will  necessarily  work in  dogs  and  
cats.  Each  compound  will  require  testing  in  the target  spe-
cies (Cui, 2000).  
Nowaday  this  compound  is  not  under  development  for 
animals. 
GnRH-Toxin Conjugates 
Another  approach to  suppressing  GnRH involves  abla-
tion of the gonadotrophs, which are cells in the pituitary that 
have  GnRH  receptors and  secrete  LH  and FSH.  Coupling  
GnRH to  a  toxin  or  protein synthesis inhibitor  is a  way  of  
delivering the toxin or inhibitor directly to only one type of 
cell – those that have GnRH receptors. 
The  concept  is  that  the  GnRH  conjugate  (GnRH  plus  a 
toxin) will bind to the GnRH receptors in the target cells of 
the  pituitary  (gonadotrophs).  This  GnRH  receptor/GnRH 
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toxin conjugate complex will then be internalized, and the 
toxin will be released from the complex only in those specif-
ic cells, causing them to die. Then, theoretically, permanent 
sterility would result, and little or no “off-target” toxicity 
would be seen (Nett & Jarosz, 2002; Ball et al., 2006). 
The specificity of the toxin delivery is a potential issue 
related to this approach. The pituitary gland is full of other 
important cell types, such as cells that make growth hor-
mone and hormones that stimulate the thyroid and adrenal 
glands, among others. Showing that the GnRHtoxin conju-
gate is safe to other pituitary cells will be important. GnRH 
receptors are also found in nontarget tissues (e.g., the heart 
and colon); therefore theoretically these receptors could also 
internalize toxin and be killed, thus having unintended tox-
icity (Ball et al., 2006). 
 
Overview of GnRH Vaccines 
About 40 years ago, it was hypothesized that if an ani-
mal could be treated in such a way as to stimulate an im-
mune response to GnRH, the GnRH antibodies would inter-
fere with the action of GnRH and this could result in infertil-
ity. But since GnRH is a small decapeptide that is normally 
present in all mammals, it is not recognized as “foreign” by 
the immune system. The challenge to immune suppression 
of GnRH was to develop a suitable vaccine (Donovan et al., 
2012).  
Research has been conducted on GnRH vaccines for a 
number of years. In order for GnRH vaccines to be effec-
tive, the treated animal (or human) must develop an immune 
response significant enough to neutralize GnRH for a period 
of time. Since it is difficult to raise an effective immune 
response to a small self peptide, the general approach to 
constructing GnRH vaccines is to couple the small GnRH 
peptide to a large foreign protein (a hapten). A number of 
conjugates have been used to enable or attempt to enable the 
animal’s immune system to recognize the coupled protein as 
foreign and make antibodies against the complex, some of 
which will bind to and inactivate GnRH. In addition to the 
GnRH-hapten conjugate, various adjuvants are used to fur-
ther stimulate the immune response. In general, formulations 
of these GnRH vaccine preparations, when tested in labora-
tory animals, dogs, and other species, have required multiple 
injections and generated a weak, short-lived antibody re-
sponse (Sad et al., 1993; Robbins, 2004; Wang et al., 2010). 
The GonaCon vaccine induces a long-lasting contracep-
tive response with a single injection; a single shot can suc-
cessfully keep female mammals infertile for 1 to 4 years 
without boosting, and infertility is reversible over time as 
antibody levels decline. GonaCon has been shown to pro-
duce high GnRH antibodies and prevent pregnancy in sever-
al species – deer, wild rats, squirrels, cats, dogs, domestic 
and feral pigs, rabbits, coyotes, wild horses, and bison – 
following a single dose (Fagerstone, 2006). 
 
Chemical Sterilants 
Current commercialized chemical sterilants for dogs 
and/or cats are administered via injection directly into the 
testis, though one approach under development is adminis-




Zinc solutions that cause testicular degeneration and 
permanent sterility have been developed for direct in-
tratesticular injection. One such solution consisting of zinc 
gluconate and L-arginine was developed, approved by the 
CVM under the trade name Neutersol® in 2003, and then 
withdrawn from the US market in 2005, apparently due to 
issues between the manufacturing and marketing companies. 
The formulation was for use in male dogs 3-10 months of 
age for chemical (non-surgical) sterilization. A zinc glu-
conate/arginine/dimethyl sulfoxide (DMSO) product called 
Infertile® was launched by Rhobifarma Industria Farmaceu-
tica Ltda in Brazil in March of 2009. 
Available information indicates that a single treatment 
with Infertile provides permanent sterilization for 72 % of 
dogs (Oliveira et al., 2013). 
 
Calcium Chloride 
Research on use of calcium chloride as an intratesticular-
injection for sterilization of dogs “and other large mam-
mals” was reported as early as 1978. Use in cats was report-
ed by Jana and Samanta at the 4th International Symposium 
on Non-Surgical Contraceptive Methods of Pet Population 
Control in 2010, who noted that ease of injection is the pri-
mary “practical advantage” of this approach, while “the 
primary disadvantage is slow onset of action (4–6 weeks) 
and inter-individual variability in level of discomfort during 
injection”. The latter may be addressed by basing injection 
volume on testicular volume rather than body weight. 
In a study of sterilization of 24 male stray dogs with a 
single injection into each testicle of calcium chloride, a 5-, 
10-, 15-, or 20-mg dose in dogs caused significant atrophy 
of testicular tissue. Epididymal sperm counts and testos-
terone concentrations were significantly decreased at all 
doses. The 15- and 20-mg doses provided a higher level of 
efficacy than the two lower doses. This method of chemical 
sterilization was found to be economical and effective, with 
no adverse effects noted. All animals tolerated the in-
tratesticular injections of calcium chloride and exhibited a 
slight increase in firmness of testis on palpation. Most dogs, 
including those injected with normal saline, displayed signs 
of mild discomfort approximately 1 to 5 minutes after injec-
tion. Researchers attributed this to fluid pressure. Every dog 
had mild testicular swelling by 24 hours after injection, and 
swelling was most evident in treated dogs between 48 and 
72 hours post-injection. The swelling decreased gradually at 
3 weeks. Injection of 5 mg of calcium chloride did not in-
duce uniform results as evaluated by histology after removal 
of the testes. Significant morphological changes were asso-
ciated with the 10 mg dose, and the 15 mg dose “resulted in 
total necrosis in seminiferous tubules and interstitial Leydig 
cells, with replacement by a fibrocollagenous band.” Re-
searchers were able to palpate only a “small testicular rem-
nant” at 4 weeks after the 20 mg calcium chloride injection. 
The maximum responses in both the biochemical and histo-
logical parameters related to chemo-sterilization were noted 
at the 15- or 20-mg doses (Leoci et al., 2019; Jana &  
Samanta, 2007). 
In a study reporting on the use of calcium chloride in the 
cat, cats (6/group) received a single bilateral intra-testicular 
injection of 0.25 ml 5 %, 10 %, or 20 % calcium chloride 
dehydrate containing 1 % lignocaine hydrochloride per 
testis: “At Day 60 post-injection, cat testes were collected 
and examined, and showed complete testicular necrosis and 
replacement by fibrous tissue; very low sperm counts; and 
reduction of serum testosterone by at least 70 % in 20 % 
dose. Androgenic enzyme activities and their expressions 
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were also reduced in all the treated groups … intra-testicular 
testosterone concentration was also low. Increased testicular 
lipid peroxidation, with reduced antioxidants and mitochon-
drial  membrane  potential,  were  evident  following  calcium  
chloride treatments” (Jana & Samanta 2010). 
The authors concluded that “efficacy of calcium chloride 
[at  40  mg]  in  inducing  sterilization  was  supported  by  the  
necrosis  of  the  seminiferous  tubules  and  interstitial  cells,  
along  with  the  significant  fibrosis.  Results  indicate  that  
intratesticular  injection  of  calcium  chloride  (40  mg)  is  a  
well-tolerated and effective method for non-surgical chemi-
cal sterilization of male cats (Leoci et al., 2019). 
 
Chlorhexidine Digluconate 
One  group  was  treated  with  2  ml  of  5 %  chlorhexidine  
solution injected percutaneously into the dorsal cranial por-
tion of both testes, and the second group injected with 1 ml 
of saline solution. Researchers monitored testosterone in all 
dogs  every  week  for  60  days.  Chlorhexidine-treated  dogs  
showed testicular tenderness and local swelling at 96 hours 
post-treatment, which regressed within 15 days. At Day 60, 
testicular ultrasonography revealed bilateral nodular lesions. 
Libido  was  reduced  and  prostatic  volume  and  parenchyma  
were normal.  Analysis of semen indicated azoospermia and 
a  substantial  decrease  in  the  volume  of  ejaculate.  Control  
animals showed no changes in libido, semen quality, testicu-
lar, epididymal or prostatic characteristics. Following surgi-
cal  castration  at  Day  60,  “longitudinal  sections  of  testes  
revealed an area of necrosis and fibrosis beside the epididy-
mis  extended  to  the  tubuli  seminiferi  recti,  rete  testis  and  
ductuli  efferentes;  histological  examination  showed  degen-
eration of the seminiferous tubules associated with a signifi-
cant alteration of the germinal epithelium cells … [research-
ers  concluded  that]  a  single  percutaneous  administration of  
5 % chlorhexidine digluconate solution into the testicular  
parenchyma should be considered an effective non-surgical 
sterilization  method  without  local  or  systemic  adverse  ef-
fects (Cathey & Memon, 2010). 
 
Hypertonic Saline 
A study conducted in 40 rats compared orchiectomy ver-
sus an injection of a  hypertonic  (20 %) saline  solution  into  
the testicles of laboratory rats. Twenty rats were treated with 
hypertonic  saline  and  20 rats  were  orchiectomized.  The  
study was undertaken to investigate an alternative, minimal-
ly  invasive  approach  to  castration  in  human  patients  with  
metastatic carcinoma (Leoci et al., 2019). 
At 30 days after injection, the rat testes were slightly at-
rophied,  and  testosterone  levels  were  similar  to  those  for  
animals  that  had  an  orchiectomy.  Histologically,  the  epidi-
dymis  was  unaffected  by  the  saline  injection.  Adverse  ef-
fects  were  not  observed  in  treated  animals.  Researchers  
indicated  that  “intratesticular  hypertonic  saline  injection  
seems to be an alternative method in the future to its rivals  
such as orchiectomy and medical castration” but that further 
laboratory work would be required to ascertain the potential 
utility of this approach in dogs. 
Note  that  advantages  and  disadvantages  may  vary  de-
pending on the specific approach. 
 
Sex Steroids 
Hormonal  down-regulation  involving the  administration 
of  exogenous  steroid  hormones  can  serve  as  a  method of 
suppressing fertility. These drugs act, in general, via several 
mechanisms,  which  may  include  suppression  of GnRH 
through negative feedback or by direct effects on the sperm 
transport, or other mechanisms. 
A  variety  of  modified  versions  of  the  sex  steroids  have 
been  synthesized  and  are  used  for  therapeutic  purposes in 
human  and  animal  medicine  (Okkens et  al.,  1981).  These 
drugs  work  through  negative  feedback  at  the  level  of  the 
brain and pituitary.  They reduce the level of GnRH, impair 
fertility and have local effects on the reproductive tract that 
interfere with fertility. However, they may have a number of 
side effects which can make them undesirable therapies for 
cats and dogs (Max et al., 2015). 
 
Progestins 
Progestins are a class of compounds that are structurally 
similar  to  progesterone,  and  mimic  its  biological effect. 
Based  on  the  principles  of  negative  feedback  exogenous  
progestins should suppress gonadotropin secretion in males, 
thereby disrupting spermatogenesis (England, 1997).  
In  male  dogs,  semen quality  did  not  change  or  changed 
insignificantly when MGA was administered orally; subcu-
taneous administration  of  MPA (medroxyprogesterone ace-
tate)  at  4  mg/kg  or  10  mg/kg  did  not  affect  sperm quality; 
“however,  subcutaneous  administration  of  MPA 20  mg/kg  
produced  rapid  response  (within  3  days)  with significant 
decreases  in  sperm  motility,  morphology  and output”  
(Kutzler & Wood, 2006).  
Use of progestinsin male cats increases the tendency to-
wards diabetes, mammary tumors,  fibroepithelial  mammary 
hyperplasia, adrenocortical  suppression,  and  other  side  ef-
fects seen in queens (Donovan et al., 2012). 
There  have  been  no  progestin  drugs  that  have  beenap-
proved by regulatory bodies for use in male dogs or cats. 
 
Gene Silencing 
One  potential  approach  to  non-surgical  contraception is 
gene silencing, which essentially involves turning off genes 
that  code  for  proteins  essential  for  reproduction.  It is  be-
lieved that gene silencing would be unlikely to reach 100 % 
efficacy,  although  levels  of  95 %  to  99 %  are  regarded as 
quite possible (Whitcomb, 2010). It is not known what level 
ofsilencing  would  be  required  for  permanent  sterilization. 
Agents  that  can  be  used  for  gene  silencing  include small 
interfering RNA (siRNA) that  can bind to  specific messen-
ger RNA (mRNA) molecules and increase or decrease their 
activity;  and  chemically modified oligonucleotides,  such as  
antisense  oligonucleotides,  that bind  to  complementary  
sequences in DNA and RNA and disrupt  their  transcription 
or  translation. At  a  2009  ACC&D  Scientific  Think  Tank,  
Gene Silencing Potential for Sterilization of Cats and Dogs, 
participants identified  some of  the  ways  that  a  gene  silenc-
ing agent might be delivered into a target cell, discussed the 
research that  would  need  to  be  undertaken  to  better  under-
stand the molecular aspects of male and female dog and cat 
reproduction, and  discussed  the  potential  regulatory  and 
other  practicalities  involved  in  developing  and  obtaining 
approval  for  a  product  whose  activity  is  based  on  gene si-
lencing (Dissen et al., 2012).  
 
Kisspeptin and  Gonadotropin-Inhibitory  Hormone 
(GnIH) 
Kisspeptins,  which  were  identified  in  2001,  are  ex-
pressed in  neurons  of  the  hypothalamus. These  neurons  
synoptically contact GnRH neurons and they express steroid 
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hormone  receptors.  Their  responses  to gonadal  steroids  
suggest that depending on their location, kisspeptin neurons 
are involved in the negative feedback regulation of gonado-
tropin secretion or may contribute to generating the preovu-
latory  gonadotropin surge  in  the  female”  (Fellman  et  al.,  
2006). 
There  may  also  be  a  role  played  by  “locally  produced 
kisspeptins” as indicated by “the ability of the LH surge to 
induce  ovarian  expression  of  KiSS-1  at  the  preovulatory 
period.  In the male,  recent  results  suggested a  downregula-
tion of the hypothalamo-pituitary-testicular axis response to 
kisspeptin following continuous administration” (Fellman et 
al., 2006). 
Researchers  note  that  kisspeptins  are  also  characterized 
by metastasis suppressor effects, “effects on motility, chem-
otaxis,  adhesion  and  invasion  have  also  been documented” 
and a system in which kisspeptin is involved affects certain 
secretory  functions  in  the  endocrine pancreas.  Signaling  in  
which  kisspeptin  is  involved  “may participate  in  implanta-
tion  of  the  mammalian  embryo, placenta  formation,  and  
maintenance of pregnancy” (Fellman et al., 2006). 
 
Targeted Delivery of Cytotoxins 
The  use  of  targeted delivery  of  cytotoxins  for steriliza-
tion in dogs and cats involves applying the power of potent 
biological toxins to kill just the cells that are targeted, in this 
case  specific  sperm,  egg,  or hormone-producing  cells re-
quired for reproduction. Three factors must converge for this 
approach to be effective (Rhodes, 2010): 
1.  A toxin has to  be purified and attached to  something 
that will take it to its target. This “transport molecule” could 
be an antibody that binds to a specific protein on a cell sur-
face, or a hormone that binds to a specific hormone receptor. 
2. The particular cell type to be destroyed has to have a 
specific “dock” for the deadly payload, to bind tightly to the 
cell  and  deliver  the  toxin  to  that  cell alone.  This  “dock”  
could  be  a  hormone receptor  or a  specific  cell  surface  pro-
tein that an antibody can grab onto. 
3. The researcher has to make sure that the “dock” is on-
ly  on  the  cells  to  be  killed  and  nowhere  else,  so  that other 
“non-target” cells in other parts of the body are not harmed, 
causing unwanted side effects.” 
In addition, if the effect is to be permanent, and only re-
quire  one treatment,  the destroyed tissue must  be unable to 
regenerate (Levy, 2010). 
 
Single-Dose Non-Hormonal Male and Female Sterilant 
At  the  4th  International  Symposium  on  Non-Surgical 
Contraceptive  Methods  of  Pet  Population  Control  in 2010, 
Drs. Joseph S. Tash and Katherine F. Roby of the Center for 
Reproductive Sciences at the University of Kansas Medical  
Center  (KUMC)  described  KU-AS-272, an  antispermato-
genic  targeting  the  testis  and  causing sterilization  of  male  
rats  following  a  single  high  dose.  Since the  ovary  contains  
the  same  protein  KU-AS-272  protein targets  and  homolo-
gous  granulosa  cells,  data  have  shown that  a  single  oral 
administration of KU-AS-272 in female mice reduced ovari-
an weight and endocrine hormones. The researchers’ goal is 
to develop KUAS-272 as a single-dose sterilant in both male 
and female dogs and cats (Tash & Roby, 2010). The effects 
of several  KU-AS-272 dose levels  administered to  rats and 
concluded that “the data collected thus far indicate that KU-
AS-272  at  12  mg/kg  and higher  may  have  achieved  the  
desired  sterilizing  block  to spermatogenesis  with  total  loss  
of  spermatogenic  cells” Researchers  are  expecting  60-day 
data,  pending  at  the  time of  this  publication,  will  ascertain  
whether sterilization was in fact attained. Mating trials in the 
rats and additional proof-of-concept studies in dogs and cats 
are planned (Gupta et al., 2012). 
 
FSH Receptor Ligand-Cytotoxin Conjugates 
Cytotoxins  that  target  the  follicle-stimulating  hormone 
receptor  (FSHR),  a  protein  found  in  specific  cells  of  the 
male  and  female  reproductive  systems  that  are  crucial for 
fertility,  may  act  as  potential  chemosterilants.  Dr. William 
Ja,  a  professor  at  the  Scripps  Research  Institute in  Florida,  
has been working on such an approach for developing can-
cer  therapeutics,  and is  now applying the same principle  to 
ablating  Sertoli  and  granulosa  cells  to cause  permanent  
sterility  in  animals.  His  work  involves developing  a  com-
pound by combining a ligand, that is, a molecule that binds 
to  a  receptor  on  a  cell,  with  a toxic  molecule  (Jana  &  
Samanta, 2010). 
 
Reversible  Inhibition of  Sperm under Guidance (RI-
SUG) 
RISUG®,  a  chemical  complex  of  styrene  maleic anhy-
dride and DMSO, is being developed as a sterilant for  men 
under  the  trademark Vasagel™ (in the  US).  The product is  
intended  for  contraception  and  suppressing testosterone  in  
men. 
Work  in  the  rat  and  the  monkey  indicate  that  once  the 
drug  is  injected  into  the  epididymis,  a  stable  “implant”  is 
created, which leads to azoospermia and contraception (Yan 
Cheng & Mruk, 2010). 
Delivery  of  the  drug  into  the  testes  impedes  testicular 
blood circulation, all of which together lead to regression of 
the seminiferous tubules along with the Sertoli cells and the 
testicular  interstitial  tissue  and  its  contained Leydig  cells.  
Thus,  the  source  of  testosterone  production  is  depleted  
(Lohiya et al., 2014).  
According to the researchers “this method may potential-
ly be a good technique for obtaining contraception and tes-
ticular  tissue regression and may be quite  effective in  male  
dog sterilization” (Chauhan & Guha, 2010). 
 
Sperm  Protein  Reactive  with  Antisperm Antibodies 
(SPRASA)  
In 2004, Chiu et al., University of Auckland, reported on 
the discovery of SPRASA, which is a sperm protein targeted 
by  anti-sperm  antibodies  in  some  men  who  are infertile. 
Since “only [antisperm antibodies]  from infertile men react  
with  SPRASA [it  is  suggested]  that  this  novel protein  may  
be important in the processes of fertility.” 
The  Department  of  Obstetrics  and  Gynecology  at  the 
university  is  studying  the  role  of  SPRASA  in  human and 
animal infertility. Dr. Larry Chamley, an author of the 2004 
publication, has received a Michelson Grant in Reproductive 
Biology  to  study  the  immunocontraceptive potential  of  
SPRASA. A 2008 publication (Wagner et al.) coauthored by 
Dr.  Chamley described  SPRASA  as  highly  conserved,  
demonstrated that SPRASA is expressed by oocytes as well 
as sperm,  and suggested that  “this  protein has an important 
function  in fertility.”  Dr.  Chamley  has  also  studied  the  re-
sponses  of possums,  considered  an  invasive  pest  in  New  
Zealand, to immunocontraceptive vaccines. Responses were 
found to vary. 
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3. Conclusions
Non-surgical methods of contraception and regulation of 
sexual function are an excellent alternative to surgical cas-
tration, when it is necessary to suppress the reproductive 
function of males for a certain time in order to treat diseases 
of the prostate gland and reduce aggressive behavior. 
Also, non-surgical methods of contraception are good in 
the case of complete and irreversible suppression of repro-
ductive function in males who do not want surgical interven-
tion (contraindications to surgery, age, intolerance to the 
components of anesthesia), as well as for stray dogs for the 
purpose of humane treatment (no postoperative complica-
tions, do not require care, methods are simple and quick to 
use). 
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